Mitomycin gel shows promise in patients with UTUC and imperative indications for therapy
May 3rd 2023“The results of the study imply that UGN-101 is not only a renal-preserving therapy for UTUC in this comorbid population, but could potentially delay the time to dialysis or radical nephroureterectomy," says Kyle M. Rose, MD.
Early stent removal following radical cystectomy does not increase risk of UTI, urine leak
May 2nd 2023"At our institution, we used a [quality improvement] protocol to first decrease overall antibiotic duration from the more standard 30 days, and then we further decreased it along with ureteral stent decrease,” says Jessica Wenzel, MD, MPH.
Removal of sacral neuromodulation devices in office found to be safe and efficacious
April 26th 2023"This is something [that is] a lot easier for the patient, it's a lot less costly to the health care system to stay out of the operating room, and it's a lot quicker for me," says Howard B. Goldman, MD.
Study identifies disparities in prostate cancer screening for transgender women
April 18th 2023“There is a lack of information regarding the prevalence and implications of [prostate cancer] in transgender women, and this highlights the crucial need for further research into prevention, detection, and treatment," says Hayley Premo.
Step therapy for OAB imposes burdens for patients, expert says
April 17th 2023"The evidence is starting to show us that although efficacy in terms of managing OAB symptoms may be equal or similar across studies for these 2 classes of medications, safety and tolerability are very different," says A. Lenore Ackerman, MD, PhD.
Intravesical chemotherapy device shows promise in muscle-invasive bladder cancer
April 14th 2023"Our preliminary clinical trial found that TAR-200 was generally safe, well tolerated, and had beneficial effects on bladder cancer outcomes in a group of patients with limited treatment options," said Mark Tyson, MD, MPH.
Study identifies biomarkers predictive of response to immunotherapy in patients with kidney cancer
April 7th 2023In combination, the number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and the mutations of PBRM1 can serve as biomarkers of response to immunotherapy in patients with kidney cancer.
Disparities found in clinical trial participation for patients with renal cell carcinoma
April 3rd 2023“These disparities are concerning as the generalizability of clinical trial results relies on the assumption that the population of patients included in a clinical trial represents the overall population of patients with the disease," says Brian M. Shinder, MD.
Rapid genetic testing model found feasible for patients with prostate cancer
March 31st 2023"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.
How the ongoing shortage of 177Lu-PSMA-617 in the US affects care for patients with prostate cancer
March 28th 2023"Some of these patients newly referred don't have any other proven therapies remaining...This is the only one on the shelf that has a proven benefit. Unfortunately, we can't offer them that at this stage," says Praful Ravi, MD, BChir, MRCP.